Table 3.
Parameters of mineral metabolism at baseline and final follow-up at study end (12 weeks) in various subgroup analyses (study participants with baseline 25(OH)D levels <40 nmol/L and with baseline 25(OH)D levels ≥40 nmol/L; study participants with a baseline body mass index (BMI) <25 kg/m2 and with a baseline BMI ≥25 kg/m2; study participants with baseline total testosterone levels <10.41 nmol/L and with a baseline total testosterone levels ≥10.41 nmol/L) with available values at both study visits.
| Baseline Visit | Study End | Treatment Effect | |||||
|---|---|---|---|---|---|---|---|
| Median | IQR | Median | IQR | Between Group Differences with 95% CI | p-Value | ||
| Men with baseline 25-hydroxyvitamin D levels <40 nmol/L | |||||||
| 25-hydroxyvitamin D (nmol/L) | |||||||
| Vitamin D (n = 19) | 34 | 30–37 | 86 | 74–107 | 45.2 | 29.4 to 64.4 | <0.001 |
| Placebo (n = 16) | 29 | 23–36 | 38 | 27–60 | |||
| Parathyroid hormone (pg/mL) | |||||||
| Vitamin D (n = 19) | 56.0 | 39.8–71.4 | 47.4 | 37.3–67.2 | 2.3 | −7.3 to 12.0 | 0.625 |
| Placebo (n = 16) | 47.8 | 42.2–63.0 | 47.2 | 40.0–53.4 | |||
| Men with baseline 25-hydroxyvitamin D levels ≥40 nmol/L | |||||||
| 25-hydroxyvitamin D (nmol/L) | |||||||
| Vitamin D (n = 77) | 58 | 49–71 | 105 | 86–116 | 35.5 | 28.8 to 42.2 | <0.001 |
| Placebo (n = 80) | 57 | 48–69 | 68 | 55–79 | |||
| Parathyroid hormone (pg/mL) | |||||||
| Vitamin D (n = 75) | 45.6 | 36.2–54.4 | 45.4 | 33.9–55.9 | −6.4 | −11.0 to −1.9 | 0.005 |
| Placebo (n = 79) | 42.8 | 35.8–52.4 | 49.6 | 38.5–62.2 | |||
| Men with a baseline BMI <25 kg/m2 | |||||||
| 25-hydroxyvitamin D (nmol/L) | |||||||
| Vitamin D (n = 30) | 56 | 44–70 | 110 | 86–119 | 43.8 | 31.7 to 55.9 | <0.001 |
| Placebo (n = 32) | 48 | 38–64 | 72 | 36–80 | |||
| Parathyroid hormone (pg/mL) | |||||||
| Vitamin D (n = 30) | 46.6 | 33.7–54.0 | 41.6 | 31.5–50.1 | −9.1 | −17.4 to −0.8 | 0.033 |
| Placebo (n = 32) | 40.2 | 30.6–48.8 | 46.0 | 35.1–64.8 | |||
| Men with a baseline BMI ≥25 kg/m2 | |||||||
| 25-hydroxyvitamin D (nmol/L) | |||||||
| Vitamin D (n = 66) | 52 | 42–68 | 54 | 43–67 | 34.9 | 27.7 to 42.0 | <0.001 |
| Placebo (n = 64) | 95 | 84–112 | 63 | 54–76 | |||
| Parathyroid hormone (pg/mL) | |||||||
| Vitamin D (n = 64) | 46.7 | 37.9–61.1 | 48.7 | 38.4–62.7 | −3.0 | −7.6 to 1.6 | 0.199 |
| Placebo (n = 63) | 45.0 | 37.2–56.7 | 51.8 | 40.9–61.0 | |||
| Men with baseline total testosterone levels <10.41 nmol/L | |||||||
| 25-hydroxyvitamin D (nmol/L) | |||||||
| Vitamin D (n = 47) | 56 | 44–72 | 89 | 83–110 | 32.3 | 23.3 to 41.3 | <0.001 |
| Placebo (n = 47) | 53 | 42–63 | 62 | 52–76 | |||
| Parathyroid hormone (pg/mL) | |||||||
| Vitamin D (n = 46) | 45.4 | 35.2–58.0 | 48.6 | 37.3–60.2 | −0.9 | −5.7 to 4.0 | 0.727 |
| Placebo (n = 47) | 43.1 | 36.3–55.2 | 49.9 | 37.1–58.2 | |||
| Men with baseline total testosterone levels ≥10.41 nmol/L | |||||||
| 25-hydroxyvitamin D (nmol/L) | |||||||
| Vitamin D (n = 49) | 52 | 42–65 | 107 | 89–119 | 42.1 | 33.6 to 50.6 | <0.001 |
| Placebo (n = 49) | 51 | 43.68 | 69 | 46–79 | |||
| Parathyroid hormone (pg/mL) | |||||||
| Vitamin D (n = 48) | 49.5 | 37.0–55.6 | 45.0 | 33.9–53.2 | −9.8 | −15.3 to −2.2 | 0.009 |
| Placebo (n = 48) | 44.5 | 35.8–50.2 | 48.6 | 39.9–65.4 | |||
Data are shown as medians and interquartile range. Treatment effects with 95% confidence interval and p-values were calculated by ANCOVA for group differences at follow-up with adjustment for baseline values. IQR = interquartile range.